Implantica AG (IPLTF) Analyst/Investor Day Transcript

SA Transcripts 162.18K Followers Follow Implantica AG ( IPLTF ) Analyst/Investor Day September 9, 2026 8:00 AM EDT Company Participants Andreas Öhrnberg - Chief Financial Officer Tomas Puusepp Peter Forsell - Founder & CEO Amit Kukreja - Chief Market Access & Strategy Officer Juanita Eberhart - Vice President of Marketing & Advocacy Conference Call Participants John Lipham Filip Wiberg - Pareto Securities AS, Research Division Daniel Sanchez Mr Ahmed R Ahmed Sallyann Warner Conversation Andreas Öhrnberg Chief Financial Officer We welcome viewers, both you who are joining us live here on site as well as those joining us live on the stream. Today, we are gathered for the Capital Markets Day of Implantica. We will hear from the company's management as well as surgeons and even patients surrounding RefluxStop that has recently gained a PMA approval from the FDA. But without further ado, I would like to welcome up Tomas Puusepp, who is the Board member of the company, who will give you all a more formal welcome. Go ahead, Tomas. Tomas Puusepp Thank you so much. Can you hear me? Okay. Great. Good afternoon, everyone, and a very warm welcome to Implantica's Capital Market Day. My name is Tomas Puusepp. I've been at the Board 6 -- more than 6 years now and followed Implantica very closely, both when you're looking into the vision, the beautiful vision we had, but also seeing how everything has evolved into something which is really substantial. And so I'm very pleased to be here and have a small introduction about that. Today, if you're looking also what's happened now with the FDA clearance, sorry, FDA approval. I've been in the industry for 40 years. And when I look into what has been achieved also by Implantica because when you do -- when you just get the product cleared or approved in FDA, that is one thing. But actually when you get the methodology and new